Opinion of the Transparency Council – sorafenib
At its meeting on 17 February 2025, the Transparency Council adopted opinion No. 31/2025 on the transfer of the active substance sorafenib from the B.119. drug program to the catalog of reimbursed chemotherapy drugs and the creation of a joint limit group